PIK3CA and colorectal carcinoma: Approximately 15-20% of CRC patients have PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) mutation, indicating a potential interaction between aspirin therapy and the PI3K/AKT pathway [66].